PDCD1 and non-small cell lung carcinoma: analyzed 761 individual lesions from 214 patients with non-small-cell lung cancer (NSCLC) and 290 lesions from 78 patients mismatch repair deficiency (MMRD) carcinoma treated with PD-1 monotherapy and found that LM had the least responses (15).